The drop in mortality was driven by a significant drop in cardiovascular mortality, the leading cause of death among seniors.
A decade after Medicare Part D gave America’s seniors greater access to prescription drugs, researchers from the University of Illinois have determined that the program has helped people live longer.
Mortality among the elderly has dropped by 2.2% annually, according to the findings, which were published earlier this month in the Journal of Health Economics. “This was driven primary by a reduction in cardiovascular mortality, the leading cause of death in the elderly,” the researchers wrote. The addition of Medicare Part D did not affect deaths from cancer, as treatments are covered under Medicare Part B.
The researchers calculated the value of the mortality reduction at $5 billion per year.
“A big question in health economics is, ‘Do public health insurance programs improve people’s health?’” Julian Reif, PhD, professor of finance and economics at the university, said in a statement. “You would think the answer would be obvious, but it’s a hard thing to prove. This paper provides strong evidence that health insurance programs improve health, and that reducing the price of medical care also improves health.”
Researchers examined differences in mortality between those age 66 who had been eligible for Medicare Part D for at least 1 year, and those age 64 who were not yet eligible for the program. They found a 2.2% annual decrease in the mortality rate among 66 year olds compared with the 64 year olds, driven by a 4.4% reduction in cardiovascular mortality.
"We employed detailed cause-of-death mortality records for the entire US population, which allowed us to measure mortality, a relatively rare event, very precisely," Reif said. "A lot of other studies can't look at mortality because their sample size is too small."
According to the researchers, Medicare Part D covers 39 people at a cost of $70 billion a year. Besides computing the value of living longer, the researchers looked at other studies to compute non-health benefits and computed a total benefit of $20 billion a year.
But finding the value of Medicare Part D isn’t just about the cost of the drugs minus the computed benefit.
There’s certainly more to health than how long you live,” Reif said. “We look at mortality because it’s easy to measure. But you take prescription drugs not just to live longer, but also to relieve pain or to manage symptoms. There are quality-of-life benefits as well that come from healthcare; it’s just harder to measure those.”
Reference
Huh J, Reif J. Did Medicare Part D reduce mortality? J Health Econ. 2017; 53:17-37. http://dx.doi.org/10.1016/j.jhealeco.2017.01.005
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More